Open Veils · Answer
What kills archaea that bacteria protocols miss?
Archaea occupy a biochemical kingdom so structurally alien that virtually every mainstream antibiotic protocol slides off them. Their cell walls, membranes, and ribosomes diverge enough from bacteria that dedicated archaeacidal strategies — pseudomurein-targeting enzymes, ether-lipid disruption, and specific aminoglycosides — are required. The emerging research picture suggests archaea are a vast, barely-mapped reservoir of novel antimicrobial chemistry that standard microbiology has ignored for decades.
Evidence
- At the membrane level, archaeal lipids are ether-linked isoprenoids rather than ester-linked fatty acids, inverting the stereochemistry of the glycerol backbone entirely.
- Bacteria are killed by disrupting peptidoglycan — their rigid cell-wall polymer — but archaea replaced peptidoglycan with pseudomurein, S-layer glycoproteins, or methanochondroitin depending on genus.
- Rifaximin, beta-lactams, and glycopeptides are therefore inert against archaea.
- In clinical SIBO contexts, regenerated.com (Jan 2026) confirms rifaximin alone has poor efficacy against methane-producing archaea, while neomycin — an aminoglycoside — retains direct activity against methanogens, which is why dual-antibiotic protocols exist for methane-dominant SIBO.
- Archaea, in other words, have evolved their own bactericidal arsenal.